Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 induction dose study of ABP-700 in healthy adults
NL-OMON19900Phase 1Recruiting
- Sponsor
- The Medicines Company
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of moxetomidate, sponsored by The Medicines Company. Primary endpoints: Safety and tolerability of induction doses of ABP-700 and Dosing regimens and pharmacodynamic conditions for induction of general anesthesia. Started Nov 2015; status: recruiting.
02
Drugs
moxetomidate
Beyond the preview
Go deeper on NL-OMON19900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19900.